TY  - CONF
AU  - Casarrubios, M.
AU  - Cruz-Bermudez, A.
AU  - Sierra-Rodero, B.
AU  - Nadal, E.
AU  - Insa-Molla, M. A.
AU  - Garcia-Campelo, M. R.
AU  - Garcia-Benito, C.
AU  - Domine-Gomez, M.
AU  - Majem-Tarruella, M.
AU  - Rodriguez-Abreu, D.
AU  - Martinez, A.
AU  - De-Castro-Carpeno, J.
AU  - Cobo-Dols, M.
AU  - Lopez-Vivanco, G.
AU  - Vinolas-Segarra, N.
AU  - Barneto-Aranda, I. C.
AU  - Viteri, S.
AU  - Massuti-Sureda, B.
AU  - Provencio-Pulla, M.
PY  - 2022
DO  - 10.1016/j.annonc.2022.02.189
SN  - 0923-7534
UR  - http://hdl.handle.net/10668/21894
T2  - Annals of oncology
AB  - Background: Neoadjuvant chemoimmunotherapy (CI) for NSCLC is a promising strategy that yields high rates of complete pathological responses (CPR) that are associated with long-term survival. We analyzed the tumor microenvironment by using gene...
LA  - en
PB  - Elsevier
KW  - Tumor Microenvironment
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Gene Expression Profiling
KW  - Humans
KW  - Neoadjuvant Therapy
KW  - Biomarkers
KW  - Immunity
TI  - Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
TY  - conference output
VL  - 33
ER  -